YOLFTbeta
47

Rznomics

476830 · KQ · Healthcare / Biotechnology

20,100.00KRW-750.00 (-3.60%)

Price History

Full chart

Market Stats

Previous Close20,850.00
Open21,100.00
Day Range20,100.00 – 21,800.00
52-Week Range19,990.00 – 122,625.00
Volume147.60K
Market Cap789.76B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
50-Day Avg28,741.00
200-Day Avg61,676.50

About

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Seong-Wook Lee
  • Headquarters#801 Innovalley Bldg. C, Seongnam-si, South Korea, 13486, Korea
  • Websitehttps://www.rznomics.com

Leadership

  • Mr. Seong-Wook LeeCEO, President & Representative Director · b. 1963
  • Mr. Rim Jong-SunCFO, Head of Financial Planning Division & Director · b. 1978
  • Mr. Seung-Ryul HanExecutive Director and Director of Research & Development · b. 1981
  • Mr. Sung-Woo HongChief Development Officer & Director · b. 1978
  • Mr. Sangkyun KimHead of Management Planning · b. 1980

Financials

Income Statement

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Revenue-143.61M-7.92B
Gross Profit-143.61M-7.92B
Gross Margin-100.00%-100.00%
Operating Expense-15.67B-22.52B
Operating Income-19.19B-15.52B-12.86B-14.60B
Operating Margin--10808.72%--184.31%
EBITDA-28.01B-8.90B-13.13B-98.82B
EBITDA Margin--6196.63%--1247.75%
Net Income-31.53B-13.60B-18.85B-103.81B
Net Income Margin--9469.95%--1310.76%
R&D13.64B10.13B8.41B15.07B
R&D as % of Total Revenue-7051.37%-190.33%
Interest Expense2.82B3.75B4.64B2.97B
Interest Expense % of Total Revenue-2607.85%-37.55%

Balance Sheet

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Total Assets35.44B20.21B28.15B62.83B
Total Liabilities98.03B94.94B121.36B3.96B
Total Equity-62.59B-74.73B-93.22B58.88B
Cash5.09B11.66B11.90B17.62B

Cash Flow

Currency: KRW2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.49B-14.37B-11.24B-10.85B
Capital Expenditure675.13M506.54M310.02M121.38M
Free Cash Flow-15.16B-14.87B-11.55B-10.97B
FCF to OCF104.66%103.53%102.76%101.12%

Earnings

Report DateDec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---
EPS Actual-193.58-278.51-228.15
Surprise---
Timing---

Key Statistics & Ratios

Market Cap789.76B
Enterprise Value682.59B
Trailing P/E0.00
Forward P/E0.00
Price / Sales357.74
Price / Book15.38
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding28.06M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 29, 20262:1